Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (291-300 of 440) with videos related to

Pageof 44
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 TrialMeletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseRazelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
Molecular Cell|December 27, 2011
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolismTaro Hitosugi, Jun Fan, Tae-Wook Chung, et al.
British Journal of Haematology|February 8, 2018
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myelomaNiels W C J van de Donk, Tineke Casneuf, Alessandro Di Cara, et al.
JCI Insight|April 24, 2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathyJithendra Kini Bailur, Samuel S McCachren, Deon B Doxie, et al.
European Journal of Haematology|April 12, 2011
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patientsMaurizio Zangari, Monette Aujay, Fenghuang Zhan, et al.
Ophthalmology and Therapy|July 27, 2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 StudyAsim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Molecular and Cellular Biology|February 19, 2009
Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformationSumin Kang, Shannon Elf, Shaozhong Dong, et al.
Blood Cancer Journal|November 27, 2019
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasoneTimothy M Schmidt, Benjamin G Barwick, Nisha Joseph, et al.
Nature Communications|March 8, 2020
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myelomaRicha Bajpai, Aditi Sharma, Abhinav Achreja, et al.
Pageof 44

Showing results (291-300 of 440) with videos related to

Sort By:
Pageof 44
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 TrialMeletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseRazelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
Molecular Cell|December 27, 2011
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolismTaro Hitosugi, Jun Fan, Tae-Wook Chung, et al.
British Journal of Haematology|February 8, 2018
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myelomaNiels W C J van de Donk, Tineke Casneuf, Alessandro Di Cara, et al.
JCI Insight|April 24, 2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathyJithendra Kini Bailur, Samuel S McCachren, Deon B Doxie, et al.
European Journal of Haematology|April 12, 2011
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patientsMaurizio Zangari, Monette Aujay, Fenghuang Zhan, et al.
Ophthalmology and Therapy|July 27, 2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 StudyAsim V Farooq, Simona Degli Esposti, Rakesh Popat, et al.
Molecular and Cellular Biology|February 19, 2009
Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformationSumin Kang, Shannon Elf, Shaozhong Dong, et al.
Blood Cancer Journal|November 27, 2019
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasoneTimothy M Schmidt, Benjamin G Barwick, Nisha Joseph, et al.
Nature Communications|March 8, 2020
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myelomaRicha Bajpai, Aditi Sharma, Abhinav Achreja, et al.
Pageof 44